SUNLENCA

SUNLENCA, Gilead's innovative twice-a-year injectable treatment for highly treatment-experienced (HTE) patients launched at the end of 2022.​ While not the client's highest priority, we knew that setting a strong foundation for this brand would be essential as injectables become increasingly important to the HIV treatment market.

• First, we proactively conducted campaign research to learn what would resonate with an HTE audience.​

• Next, we developed a brochure for OPDP review to begin testing how we can appropriately deliver complex content to this audience.​

After completing the OPDP submission, I oversaw copy development for the brand’s first label update. Updates to the website and a new SUNLENCA patient brochure not only gave a visual and UX refresh, but up-leveled our campaign and expanded content around efficacy, safety, and dosing. ​Visit SUNLENCA.com to see the live website.